Oxford BioDynamics and its scientific advisory panel member, Dr Claudio Carini will be joining Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees, the company said Thursday.
The Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that aims to discover, develop, and seek regulatory approval for biological markers, known as biomarkers, to support new drug development, precision medicine, and medical diagnostics.
Christian Hoyer Millar, CEO of Oxford BioDynamics, said that the FNIH Biomarkers Consortium aims to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease, and that it is also a goal shared by Oxford BioDynamics.
“We believe that becoming a member of these important FNIH committees will be beneficial as we continue to progress towards our strategic aim of becoming the industry standard for epigenetic biomarker discovery,” BioDynamic’s CEO said.